Analysts forecast that Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) will report earnings per share of ($0.50) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aeglea Bio Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.63) and the highest estimate coming in at ($0.40). Aeglea Bio Therapeutics posted earnings of ($0.46) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 8.7%. The firm is scheduled to report its next earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Aeglea Bio Therapeutics will report full year earnings of ($2.14) per share for the current fiscal year, with EPS estimates ranging from ($2.58) to ($1.81). For the next financial year, analysts expect that the business will report earnings of ($1.90) per share, with EPS estimates ranging from ($2.24) to ($1.26). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Aeglea Bio Therapeutics.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04).
In related news, CEO Anthony G. Quinn acquired 6,256 shares of Aeglea Bio Therapeutics stock in a transaction that occurred on Wednesday, May 15th. The stock was purchased at an average price of $6.76 per share, for a total transaction of $42,290.56. Following the completion of the purchase, the chief executive officer now directly owns 277,152 shares of the company’s stock, valued at $1,873,547.52. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Anthony G. Quinn acquired 6,218 shares of Aeglea Bio Therapeutics stock in a transaction that occurred on Friday, May 17th. The stock was bought at an average price of $6.65 per share, with a total value of $41,349.70. Following the purchase, the chief executive officer now directly owns 277,152 shares of the company’s stock, valued at $1,843,060.80. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 92,177 shares of company stock worth $593,817. Insiders own 12.60% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA acquired a new stake in shares of Aeglea Bio Therapeutics in the first quarter valued at about $32,000. Meeder Asset Management Inc. lifted its stake in shares of Aeglea Bio Therapeutics by 38.4% in the first quarter. Meeder Asset Management Inc. now owns 7,083 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,967 shares during the period. Commonwealth Equity Services LLC acquired a new stake in shares of Aeglea Bio Therapeutics in the second quarter valued at about $68,000. Bank of America Corp DE lifted its stake in shares of Aeglea Bio Therapeutics by 299.9% in the fourth quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 12,858 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of Aeglea Bio Therapeutics in the fourth quarter valued at about $156,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.
Shares of NASDAQ:AGLE traded down $0.01 during midday trading on Monday, hitting $7.00. The stock had a trading volume of 102,877 shares, compared to its average volume of 211,361. The stock has a market cap of $202.23 million, a P/E ratio of -3.29 and a beta of 1.00. The company’s 50 day moving average price is $6.51. Aeglea Bio Therapeutics has a 1 year low of $5.99 and a 1 year high of $11.16.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Featured Article: What is a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.